IκBα (Inhibitor of NF-κB α, encoded by NFKBIA) is the prototypical member of the IκB family of proteins, serving as the primary cytoplasmic inhibitor of the NF-κB transcription factor. IκBα sequesters NF-κB dimers (primarily RELA/p50) in the cytoplasm by masking their nuclear localization signals. Upon cellular stimulation by cytokines, pathogen-associated molecular patterns (PAMPs), or stress signals, IκBα is rapidly phosphorylated by the IKK complex, ubiquitinated, and degraded by the proteasome, permitting NF-κB nuclear translocation and target gene activation[1]. IκBα is itself a NF-κB target gene, creating a tight negative feedback loop that shapes the magnitude and duration of NF-κB responses[2].
In the central nervous system, dysregulated IκBα/NF-κB signaling drives chronic neuroinflammation, microglial activation, and neuronal death in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[3][4].
bfe67bb53c3c532ef4237fa3323691ae27404769
IκBα contains six ankyrin repeat domains (ARD), each approximately 33 residues long, stacked in a domain-swapped configuration that creates the binding interface for NF-κB dimers[5]:
The ankyrin repeats adopt a slightly curved, solenoid-like structure that fits into the groove formed by the NF-κB dimer's dimerization domain, blocking DNA binding and nuclear import[6].
IκBα maintains NF-κB in an inactive state in the cytoplasm through high-affinity binding to the NF-κB dimerization domain:
NF-κB rapidly induces NFKBIA transcription, leading to IκBα resynthesis that re-sequesters NF-κB and terminates the response. This feedback loop typically limits NF-κB activation to 1-2 hours after stimulation[7].
IκBα can undergo proteasome-independent processing, generating a truncated form that translocates to the nucleus and modulates gene expression independently of NF-κB inhibition.
IκBα/NF-κB signaling is chronically dysregulated in AD brains[3:1]:
Dopaminergic neurons in the substantia nigra show altered NF-κB/IκBα signaling[4:1]:
IκBα is a central node in neuroinflammatory signaling[9]:
| Interactor | Relationship | Function |
|---|---|---|
| NF-κB (RELA/p50 dimer) | Direct binding | Cytoplasmic sequestration |
| IKK complex | Substrate of | Phosphorylates Ser32/Ser36 |
| β-TrCP (FBXW11) | E3 ligase | Recognizes phosphorylated IκBα |
| 26S Proteasome | Degradation target | Degrades ubiquitinated IκBα |
| HDAC1/2/3 | Co-repressor complex | Represses NF-κB target genes in nucleus |
| Property | IκBα | IκBβ | IκBε |
|---|---|---|---|
| Gene | NFKBIA | NFKBIB | NFKBIE |
| Size | 317 aa (36 kDa) | 281 aa (37 kDa) | 409 aa |
| Expression | Ubiquitous, inducible | Restricted, constitutive | Neuron-enriched |
| NF-κB selectivity | All canonical dimers | RELA/c-Rel dimers | p50 homodimers |
| Degradation kinetics | Fast (minutes) | Slower, sustained | Slowest |
| Feedback | Strong (rapid resynthesis) | Moderate | Weak |
bfe67bb53c3c532ef4237fa3323691ae27404769
Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell. 2022. ↩︎
Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy. 2023. ↩︎
Romano M, Scilabra M, D'Andrea R, et al. NF-κB as a therapeutic target in neurodegenerative diseases. Neurobiology of Disease. 2022. ↩︎ ↩︎
Shih RH, Wang CY, Yang CM. NF-κB and its role in neuroinflammation. Journal of Neuroinflammation. 2021. ↩︎ ↩︎
Haskill S, Beg AA, Baldwin AS Jr, et al. Characterization of an immediate-early protein induced by cytokines, and its role in the regulation of NF-κB. Cell. 1991. ↩︎
Oi VT, Glimcher LH, Grosschedl R. NF-κB: a mediator of immediate-early gene responses. Trends in Biochemical Sciences. 1999. ↩︎
Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-κB: a blossoming of relevance to human disease. Cell. 2021. ↩︎
Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic approach. Annual Review of Pharmacology and Toxicology. 2020. ↩︎
Mattson MP, Meffert MK. Roles for NF-κB in the nervous system. Cell. 2020. ↩︎
Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annual Review of Immunology. 2023. ↩︎